A Study of HS-20094 in Patients With T2DM

NCT06901648 · Completed

Last updated 2026-05-28

This clinical trial is testing the safety and effects of the experimental drug HS-20094 in adults with type 2 diabetes.

Status Completed The study has finished.

Phase Phase 2 Tests whether it works and watches safety in a moderate group.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 275 people

Who can join Ages 18–75 · all sexes

Timeline Started 2024-02 · est. completion 2025-04

Where 1 site · China

What this study is testing ClinicalTrials.gov NCT06901648 ↗

Description as written by the study sponsor.

This is a 32-week, phase 2, randomized study, HS-20094 and placebo were double-blind, dulaglutide was open-label. Adults with T2D inadequately controlled with diet and exercise alone or with stable metformin, an HbA1c (glycated hemoglobin) ≥53 to ≤91 mmol/mol (≥7.0 % to≤10.5 %) were randomly assigned to receive 5 mg HS-20094, 10 mg HS-20094, 15 mg HS-20094, placebo, or 1.5 mg dulaglutide subcutaneously for 32 weeks. The primary endpoint was change in HbA1C from baseline to 32 weeks, and secondary endpoints included change in fasting glucose, body weight and several additional measures relevant for cardiovascular risks.

Treatments tested

HS-20094 Drug

Administrated by subcutaneous injection once a week
Dulaglutide Drug

Administrated by subcutaneous injection once a week
Palcebo Drug

Administrated by subcutaneous injection once a week

Main thing measured	The change of HbA1c in the patients
Sponsor	Jiangsu Hansoh Pharmaceutical Co., Ltd.
Conditions studied	Type 2 Diabetes
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06901648 ↗